Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Genitourinary 2Thoracic 1Lymphoid 1Gynecologic 1Gastrointestinal 1CNS 1Breast 1

Conditions

Triple Negative Breast Neoplasms 2Sarcoma 2Recurrence 2Neoplasms 2Glioma 2Wilms Tumor 1Sarcoma, Synovial 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Prostatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplasms, Neuroepithelial 1Multiple Myeloma 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Hodgkin Disease 1Head and Neck Neoplasms 1Gliosarcoma 1Glioblastoma 1Esophageal Neoplasms 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Desmoplastic Small Round Cell Tumor 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Doxorubicin 27Cyclophosphamide 26Radiotherapy 16Gemcitabine 16Filgrastim 11pembrolizumab 10pazopanib 10Radiation 9Docetaxel 9Cisplatin 9fludarabine 7Trabectedin 7Ipilimumab 7Ifosfamide 7Granulocyte Colony-Stimulating Factor 7Etoposide 7Carboplatin 7Busulfan 7Bevacizumab 7olaratumab 6Temozolomide 6Peripheral Blood Stem Cell Transplantation 6Nivolumab 6Mesna 6Melphalan 6selinexor 5Leucovorin 5Irinotecan 5Celecoxib 5Bortezomib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Sarcoma × CLR1404 × Clear all
NCT03478462 2026-03-18

CLOVER-2

Cellectar Biosciences, Inc.

Phase 1 Active not recruiting
30 enrolled
CNSGenitourinaryLymphoidSarcoma

Diffuse Intrinsic Pontine Glioma, Ependymoma, Glioblastoma, Glioma, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Neuroectodermal Tumors, Primitive, Neoplasms, Neuroepithelial, Gliosarcoma, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

NCT01495663 2015-02-26

Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned

Cellectar Biosciences, Inc.

Phase 1 Completed
12 enrolled
BreastGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Recurrence, Sarcoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡